Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Transforming liver care: the evolution of MASH diagnosis and treatment

Rajarshi Banerjee, MD, PhD
Meds
June 16, 2024
Share
Tweet
Share

The term “revolutionary” is used too often in health care. New imaging modalities, pharmaceutical breakthroughs, advanced medical devices, and artificial intelligence are all regularly proclaimed to be revolutionary to attract interest and attention. But those of us trained in medicine who work in these fields know that revolutions don’t happen—it takes 17 years for new research to reach the translational stage.

In reality, the best we can hope for is a fast evolution of clinical practices. Even the new class of metabolic modulators and weight loss treatments, including Zepbound and Wegovy, which can potentially bring global obesity rates down, are based on compounds developed a dozen years ago. However, when there is critical mass—”moonshot” alignment—across health care innovators, providers, policymakers, and payers, we can increase the pace of health care’s evolution and deliver patients relief very quickly.

Advances in imaging and diagnosis of MASH

That’s why what is happening today in liver care is so exciting. We are at the nexus of several concurrent advancements in imaging and pharmaceutical development that will significantly advance the evolution of clinical care for how patients with metabolic dysfunction-associated steatohepatitis (MASH) are diagnosed, treated, and monitored. For those unfamiliar with MASH, it is a form of fatty liver disease that can cause scarring in the liver, potentially leading to cirrhosis and the need for a transplant or death. Importantly, MASH is a treatable risk factor for heart disease (like cholesterol), is driven by obesity, and affects a third of the global population.

Previously, MASH was confirmed through liver biopsy, but thanks to advances in imaging, patients can now avoid the pain, inconvenience, and the 2.4 percent risk of major complications from a large needle being stuck into their liver. What’s more, if the biopsy misses the most affected part of the liver and/or the pathologists disagree on the results, a patient might be left with an inaccurate diagnosis. Recent imaging modalities have fewer limitations. Seeing the liver, in totality, with detailed data visualizations of the organ, helps physicians and patients see the affected areas, and as treatment progresses, advanced imaging can quantify the impact of treatment and predict outcomes. Upstream MRI, blood tests, and ultrasound elastography can also identify MASH without biopsy in a community setting, which is important because MASH is largely asymptomatic.

First FDA-approved treatment for MASH in 40 years 

Concurrent with these advances in imaging, pharmaceutical companies are pursuing new treatments for MASH. Recently, after 15 years of development, the FDA approved Madrigal’s drug Rezdiffra for MASH. Prior to that, there were no effective treatments in the 40 years since MASH was identified. While Madrigal was the first company to receive approval for a MASH drug, several other companies, including Akero Therapeutics, 89 Bio, and Viking Therapeutics, are all expected to seek approval for MASH drugs in the next few years. Joining the research push in this area are the makers of the GLP-1 weight loss drugs, which are also exploring their products’ viability in treating MASH.

Perhaps recognizing the important role imaging now plays in clinical trials for MASH drugs clinical trials, the FDA determined liver biopsies are not necessary for physicians to prescribe Rezdiffra. This is a moment in the evolution of MASH care that we will look back on in 10-15 years and recognize how everything has changed. Importantly, integrating scans into current and ongoing MASH therapeutic clinical trials has made it easier to introduce new MASH drugs into physician workflows.

Improving the patient journey

Using newer medical imaging products has shortened the diagnostic journey that used to take days and involve liver biopsies. Now diagnosis can be achieved in a couple of hours, allowing patients to begin treatment sooner. With the recognition that imaging results are equivalent to biopsies, noninvasive annual or semiannual scans will help physicians monitor and further customize treatment, if necessary, without inflicting unnecessary biopsy pain and risk on patients.

Madrigal spent 15 years developing Rezdiffra, and other companies will have similar timelines once their compounds are reviewed by the FDA. The use of quantitative MRIs and biomarkers to map liver disease was researched and clinically validated more than a dozen years ago. Other modalities like ultrasound elastography have been around longer. Fortunately for physicians and patients, continued advances in imaging-based diagnosis and the approval of new therapeutics are happening concurrently. Revolutions may not happen in health care, but these two exciting developments mean co-evolution is occurring, and it’s only going to get better. The use of medical imaging modalities in the lifecycle of MASH drug development and clinical care will unlock significant growth in imaging. But as important, imaging’s role in MASH can serve as an example to drug developers of how working in tandem with imaging can evolve the science of imaging to support the development of new therapeutics and, ultimately, better clinical practice.

Rajarshi Banerjee is a physician executive.

Prev

Medical students are learning to treat others, but who is caring for them?

June 16, 2024 Kevin 0
…
Next

Is the health care system broken or designed this way? [PODCAST]

June 16, 2024 Kevin 0
…

Tagged as: Gastroenterology, Medications

Post navigation

< Previous Post
Medical students are learning to treat others, but who is caring for them?
Next Post >
Is the health care system broken or designed this way? [PODCAST]

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

Related Posts

  • Diagnosis: malformation of a health care system

    Jeffrey Fraser, MD
  • The solution to a crumbling primary care foundation is direct primary care

    Sara Pastoor, MD
  • Health care’s hidden problem: hospital primary care losses

    Christopher Habig, MBA
  • Care is no longer personal. Care is political.

    Eva Kittay, PhD
  • Primary Care First: CMS develops a value-based primary care program for independent practices

    Robert Colton, MD
  • Proactive care is the linchpin for saving America’s health care system

    Ronald A. Paulus, MD, MBA

More in Meds

  • A world without antidepressants: What could possibly go wrong?

    Tomi Mitchell, MD
  • The truth about GLP-1 medications for weight loss: What every patient should know

    Nisha Kuruvadi, DO
  • The hidden bias in how we treat chronic pain

    Richard A. Lawhern, PhD
  • Biologics are not small molecules: the case for pre-allergy testing in an era of immune-based therapies

    Robert Trent
  • The anesthesia spectrum: Guiding patients through comfort options in oral surgery

    Dexter Mattox, MD, DMD
  • Functional precision oncology: a game changer in cancer therapy

    Chris Apfel, MD, PhD, MBA
  • Most Popular

  • Past Week

    • How dismantling DEI endangers the future of medical care

      Shashank Madhu and Christian Tallo | Education
    • How scales of justice saved a doctor-patient relationship

      Neil Baum, MD | Physician
    • “Think twice, heal once”: Why medical decision-making needs a second opinion from your slower brain (and AI)

      Harvey Castro, MD, MBA | Tech
    • My journey from misdiagnosis to living fully with APBD

      Jeff Cooper | Conditions
    • Do Jewish students face rising bias in holistic admissions?

      Anonymous | Education
    • Why shared decision-making in medicine often fails

      M. Bennet Broner, PhD | Conditions
  • Past 6 Months

    • What’s driving medical students away from primary care?

      ​​Vineeth Amba, MPH, Archita Goyal, and Wayne Altman, MD | Education
    • Internal Medicine 2025: inspiration at the annual meeting

      American College of Physicians | Physician
    • A faster path to becoming a doctor is possible—here’s how

      Ankit Jain | Education
    • Residency as rehearsal: the new pediatric hospitalist fellowship requirement scam

      Anonymous | Physician
    • Are quotas a solution to physician shortages?

      Jacob Murphy | Education
    • The hidden bias in how we treat chronic pain

      Richard A. Lawhern, PhD | Meds
  • Recent Posts

    • Why true listening is crucial for future health care professionals [PODCAST]

      The Podcast by KevinMD | Podcast
    • Love on life support: a powerful reminder from the ICU

      Syed Ahmad Moosa, MD | Physician
    • Surviving kidney disease and reforming patient care [PODCAST]

      The Podcast by KevinMD | Podcast
    • Why we fear being forgotten more than death itself

      Patrick Hudson, MD | Physician
    • My journey from misdiagnosis to living fully with APBD

      Jeff Cooper | Conditions
    • Antimicrobial resistance: a public health crisis that needs your voice [PODCAST]

      The Podcast by KevinMD | Podcast

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

Leave a Comment

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

  • Most Popular

  • Past Week

    • How dismantling DEI endangers the future of medical care

      Shashank Madhu and Christian Tallo | Education
    • How scales of justice saved a doctor-patient relationship

      Neil Baum, MD | Physician
    • “Think twice, heal once”: Why medical decision-making needs a second opinion from your slower brain (and AI)

      Harvey Castro, MD, MBA | Tech
    • My journey from misdiagnosis to living fully with APBD

      Jeff Cooper | Conditions
    • Do Jewish students face rising bias in holistic admissions?

      Anonymous | Education
    • Why shared decision-making in medicine often fails

      M. Bennet Broner, PhD | Conditions
  • Past 6 Months

    • What’s driving medical students away from primary care?

      ​​Vineeth Amba, MPH, Archita Goyal, and Wayne Altman, MD | Education
    • Internal Medicine 2025: inspiration at the annual meeting

      American College of Physicians | Physician
    • A faster path to becoming a doctor is possible—here’s how

      Ankit Jain | Education
    • Residency as rehearsal: the new pediatric hospitalist fellowship requirement scam

      Anonymous | Physician
    • Are quotas a solution to physician shortages?

      Jacob Murphy | Education
    • The hidden bias in how we treat chronic pain

      Richard A. Lawhern, PhD | Meds
  • Recent Posts

    • Why true listening is crucial for future health care professionals [PODCAST]

      The Podcast by KevinMD | Podcast
    • Love on life support: a powerful reminder from the ICU

      Syed Ahmad Moosa, MD | Physician
    • Surviving kidney disease and reforming patient care [PODCAST]

      The Podcast by KevinMD | Podcast
    • Why we fear being forgotten more than death itself

      Patrick Hudson, MD | Physician
    • My journey from misdiagnosis to living fully with APBD

      Jeff Cooper | Conditions
    • Antimicrobial resistance: a public health crisis that needs your voice [PODCAST]

      The Podcast by KevinMD | Podcast

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Leave a Comment

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...